SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc. Logo

April 02, 2015 07:00 ET

CTD Holdings Amends Agreement With Medical Need Europe

MNE Will Be European Distributor of New Orphan Drugs That CTD May Develop

ALACHUA, FL--(Marketwired - April 02, 2015) - CTD Holdings, Inc. (OTCQB: CTDH), a family of biotechnology growth companies that develop cyclodextrin-based treatments, today announced that it has amended its agreement with Medical Need Europe (MNE) such that MNE will be the exclusive distributor in Europe of Trappsol® Cyclo™ and any new cyclodextrin-based Orphan Drug Designated treatments that CTD may develop in the future.

MNE, which is based in Stockholm, Sweden, currently is the exclusive European distributor of CTD's orphan drug designated Trappsol® Cyclo™ for the treatment of Niemann-Pick Type C, a rare and fatal disease found primarily in children. The MNE territory includes 44 countries in which the product is currently available on a compassionate-use "named patient" basis, following special approval from the national regulatory authorities on request from a prescribing physician. Patients are currently receiving Trappsol® Cyclo™ in Norway, Bulgaria, Spain, and Switzerland and a request from Turkey is currently being processed.

"CTD is committed to providing Trappsol® Cyclo™ as quickly as possible to any patient or family who requests it, while taking care to work through all appropriate regulatory and health agencies," said CTD President and CEO Dr. Jeffrey Tate. "We are pleased to work with MNE in this expanded relationship for the benefit of patients and families across Europe."

About the CTD Holdings, Inc.: 
CTD Holdings, Inc. is a family of biotechnology growth companies based on cyclodextrin chemistry. Its individual divisions distribute and manufacture the trademarked Trappsol® and Aquaplex® cyclodextrins, cyclodextrin derivatives, and cyclodextrin complexes for biotechnology and life science companies involved in research, pharmaceutical, medical device, cosmetics and nutrition markets. Sphingo Biotechnology, Inc. is developing Trappsol® Cyclo™, an orphan drug designated product, for the treatment of Niemann Pick Type C, a rare and fatal genetic disease in young children. NanoSonic Products, Inc. operates the world's only cGMP pulse drying facility for the production of ultra-pure cyclodextrin derivatives and pharmaceutical grade Aquaplex® cyclodextrin complexes. CTD, Inc. supplies cyclodextrins to biotechnology and life science researchers around the globe from the world's largest catalog of cyclodextrins. The companies offer a wide variety of cyclodextrin related manufacturing services to worldwide customers, including custom formulation, manufacturing, and commercial scale supply of pharmaceutical grade cyclodextrin complexes. For additional information, visit the Company's websites: www.ctd-holdings.com and www.cyclodex.com

About Medical Need Europe AB:
Medical Need is a privately held pharmaceutical company headquartered in Sweden, focusing on the provision of physical access to unlicensed medicines under international named patient regulations and the registration, distribution, marketing and sale of licensed orphan drugs and niche specialty pharmaceuticals across Europe, for the treatment of rare diseases where there is a high unmet medical need.

The company is currently active within several rare and niche disorders, such as; Urea Cycle Disorders, Niemann-Pick type C, Congenital-Sucrase-Isomaltase Deficiency, progressive multiple sclerosis (MS), multi-resistant tuberculosis, hematological stem cell transplantation, brain tumors and Ménières disease

Safe Harbor Statement:
This press release contains "forward-looking statements" about the Company's current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes" and "expects" or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual results in future periods to differ materially from what is expressed in, or implied by, these statements. The factors which may influence the Company's future performance include the Company's ability to obtain additional capital to expand operations as planned, success in attracting additional customers and profitable contracts, and regulatory risks associated with producing food and pharmaceutical grade products. These and other risk factors are described from time to time in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's reports on Forms 10-K and 10-Q. Unless required by law, the Company assumes no obligation to update or revise any forward-looking statements as a result of new information or future events.

Contact Information